secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-09-18T23:59:59+00:00
Accession:  0001683168-24-006495
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma receives Nasdaq minimum bid deficiency; ineligible for cure due to reverse splits
--------------------------------------------------------------------------------

- Nasdaq notified CNS Pharma on Sept 12, 2024 that common stock failed to maintain $1.00 minimum bid for 30 consecutive days.
- Company ineligible for 180-day cure period because it effected reverse stock splits with cumulative ratio >=250 in prior two years.
- Company intends to request a hearing before Nasdaq Panel; request will automatically stay any suspension/delisting pending hearing.
- No assurance that Panel will grant an extension or that company will ultimately regain compliance with listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824006495/0001683168-24-006495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824006495/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-006495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer